IDEAYA Biosciences, Inc.

NasdaqGS:IDYA 주식 리포트

시가총액: US$2.6b

IDEAYA Biosciences 경영진

경영진 기준 점검 3/4

IDEAYA Biosciences CEO는 Yujiro Hata, Jun2015 에 임명되었습니다 의 임기는 10.92 년입니다. 총 연간 보상은 $9.51M, 7.4% 급여 및 92.6% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $20.40M 가치에 해당하는 회사 주식의 0.79% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 2.4 년과 7.5 년입니다.

핵심 정보

Yujiro Hata

최고경영자

US$9.5m

총 보수

CEO 급여 비율7.36%
CEO 재임 기간10.9yrs
CEO 지분 보유율0.8%
경영진 평균 재임 기간2.4yrs
이사회 평균 재임 기간7.5yrs

최근 경영진 업데이트

Recent updates

분석 기사 • May 08

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Just Reported And Analysts Have Been Cutting Their Estimates

IDEAYA Biosciences, Inc. ( NASDAQ:IDYA ) shareholders are probably feeling a little disappointed, since its shares fell...
분석 기사 • May 07

Some Analysts Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Estimates

Market forces rained on the parade of IDEAYA Biosciences, Inc. ( NASDAQ:IDYA ) shareholders today, when the analysts...
Seeking Alpha • Apr 08

Ideaya Biosciences: Key Pivotal Data Imminent

Summary Ideaya Biosciences is on the verge of a pivotal data readout for darovasertib, its lead uveal melanoma candidate. IDYA maintains a strong cash runway of 3–4 years, supporting a robust and expanding pipeline targeting multiple high-value oncology indications. Darovasertib has shown promising efficacy as both monotherapy and in combination, with phase 3 data expected imminently and potential for FDA approval. Despite aggressive valuation and rising cash burn, I maintain a Buy rating, confident in IDYA's strategic positioning and clinical potential. Read the full article on Seeking Alpha
분석 기사 • Jul 28

We're Keeping An Eye On IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Apr 16

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later

Summary IDEAYA Biosciences' valuation has declined over 50% since mid-2024, prompting a re-evaluation of its investment potential. The most advanced program, darovasertib, targets tumors with GNAQ/GNA11 mutations, showing promising clinical activity. With over $1 billion in cash and other investments, IDYA has 4–5 years of operational liquidity. Strength: Strong liquidity. Risk: Heavy reliance on key data catalysts for future success. Read the full article on Seeking Alpha
분석 기사 • Apr 13

Is IDEAYA Biosciences (NASDAQ:IDYA) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Feb 10

Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming

Summary Ideaya Biosciences, Inc.'s darovasertib + crizotinib combination is being explored in the potential registration-enabling phase 2/3 study targeting patients with 1st-line HLA-A2-negative metastatic uveal melanoma; mPFS data expected end of 2025. Darovasertib is also being evaluated in another phase 2 study as a monotherapy targeting neoadjuvant uveal melanoma patients, with data expected in 2025. The global uveal melanoma treatment market is projected to reach $3.22 billion by the end of 2034. IDYA is financially strong, with $1.2 billion in cash reserves, sufficient to fund operations into at least 2028, reducing near-term dilution risk. Read the full article on Seeking Alpha
분석 기사 • Jan 03

We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Dec 04

Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash

Summary Ideaya Biosciences' stock experienced volatility, with significant movements driven by clinical data releases and a secondary offering, but currently trades near its December levels. Ideaya's lead candidate, Darovasertib, shows promising efficacy in metastatic uveal melanoma, especially in combination with crizotinib, addressing a significant unmet medical need. IDE397, another key asset, demonstrated positive interim data in MTAP-deletion cancers, showing a 39% ORR and a strong safety profile. With a market cap of $2.37bn and a cash runway into 2028, IDYA is financially well-positioned, despite the inherent risks of late-stage studies. Read the full article on Seeking Alpha
Seeking Alpha • Sep 20

Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success

Summary IDEAYA Biosciences uses synthetic lethality to target genetic vulnerabilities in cancer cells, focusing on MTAP-deleted tumors. IDE397 demonstrated promising Phase 2 results with high response rates in MTAP-deleted solid tumors. Strategic partnerships with Pfizer, Amgen, Gilead, and GSK validate IDEAYA's technology and offer substantial potential milestone payments. IDE397 shows a 94% disease control rate in Phase 2 trials for MTAP-deleted tumors, with favorable safety and efficacy profiles, positioning it as a potential first-in-class treatment. IDYA has a robust cash runway and reasonable valuation, which is why I rate it a "buy" for long-term biotech investors. Read the full article on Seeking Alpha
Seeking Alpha • Jul 08

Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?

Summary Ideaya Biosciences is a cancer-focused biotech with promising pipeline candidates darovasertib and IDE397 targeting uveal melanoma and MTAP-deleted cancers. Darovasertib has shown strong results in phase 2 trials for uveal melanoma, while IDE397 demonstrated positive phase 2 data for MTAP-deleted NSCLC and urothelial cancer. With a solid financial position and potential for accelerated approvals, IDYA presents a compelling investment opportunity, although the current valuation may be high. Read the full article on Seeking Alpha
Seeking Alpha • Jun 18

Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'

Summary The stock of Ideaya Biosciences, Inc. has risen some 50% since we last visited this clinical stage development firm focused on "synthetic lethality." The company continues to advance its pipeline, has partnerships with several Big Pharma names, and has a fortress balance sheet. An updated analysis around Ideaya Biosciences follows in the paragraphs below. Read the full article on Seeking Alpha
분석 기사 • Feb 22

Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Feb 16

Ideaya Biosciences: A Strong Bet In Targeted Oncology

Summary IDEAYA Biosciences' stock has increased by 57% since September, outperforming the S&P 500. PRMT5 inhibitors have gained attention in the biotech industry, with Bristol Myers paying $5.8 billion, in part, for Mirati's PRMT5 medication. IDEAYA's second lead drug, IDE397, is a PRMT5 inhibitor being studied in combination with an Amgen drug, with worldwide commercial rights retained by IDEAYA. Given the company's strategic positioning and the high unmet medical need in its target indications, IDEAYA appears to be a promising investment with significant upside potential. Read the full article on Seeking Alpha

CEO 보수 분석

Yujiro Hata의 보수는 IDEAYA Biosciences의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
Mar 31 2026n/an/a

-US$140m

Dec 31 2025US$10mUS$700k

-US$114m

Sep 30 2025n/an/a

-US$161m

Jun 30 2025n/an/a

-US$332m

Mar 31 2025n/an/a

-US$307m

Dec 31 2024US$17mUS$646k

-US$274m

Sep 30 2024n/an/a

-US$178m

Jun 30 2024n/an/a

-US$154m

Mar 31 2024n/an/a

-US$129m

Dec 31 2023US$6mUS$598k

-US$113m

Sep 30 2023n/an/a

-US$103m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$68m

Dec 31 2022US$3mUS$570k

-US$59m

Sep 30 2022n/an/a

-US$53m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$55m

Dec 31 2021US$4mUS$544k

-US$50m

Sep 30 2021n/an/a

-US$37m

Jun 30 2021n/an/a

-US$30m

Mar 31 2021n/an/a

-US$31m

Dec 31 2020US$2mUS$510k

-US$34m

Sep 30 2020n/an/a

-US$40m

Jun 30 2020n/an/a

-US$46m

Mar 31 2020n/an/a

-US$44m

Dec 31 2019US$2mUS$457k

-US$42m

보상 대 시장: Yujiro의 총 보수(USD9.51M)는 US 시장에서 비슷한 규모 기업의 평균(USD7.05M)보다 높습니다.

보상과 수익: Yujiro의 보상은 지난 1년 동안 회사 실적과 일치했습니다.

CEO

Yujiro Hata (51 yo)

10.9yrs
재임 기간
US$9,512,640
보수

Mr. Yujiro S. Hata is Director since November 2024 at Hexagon Bio, Inc. He serves as an Independent Director at Enanta Pharmaceuticals, Inc. since August 29, 2021. He is a Co-Founder of IDEAYA Biosciences,...

리더십 팀

이름직위재임 기간보수지분
Yujiro Hata
Founder10.9yrsUS$9.51m0.79%
$ 20.4m
Joshua Bleharski
Chief Financial Officer1yrUS$4.15m데이터 없음
Andres Briseno
Chief Accounting Officer2.8yrsUS$1.65m0.030%
$ 781.7k
Michael White
Chief Scientific Officer4.6yrsUS$3.32m데이터 없음
Douglas Snyder
Chief Legal Officer1.7yrsUS$1.13m0.0024%
$ 61.5k
Darrin Beaupre
Chief Medical Officer3.5yrsUS$3.33m데이터 없음
Paul Barsanti
Chief Technology Officer3.3yrs데이터 없음데이터 없음
Francine Zelaya
Senior VP & Head of Human Resources1.9yrs데이터 없음데이터 없음
Mick O'Quigley
Senior Vice President of Medical Writing & Project Management4.2yrs데이터 없음데이터 없음
Daniel Simon
Chief Business Officer1.8yrs데이터 없음데이터 없음
Stuart Dorman
Chief Commercial Officer1.4yrsUS$3.42m데이터 없음
Jasgit Sachdev
Senior Vice President of Late Phase Clinical Development & Strategy1.3yrs데이터 없음데이터 없음
2.4yrs
평균 재임 기간
51yo
평균 나이

경험이 풍부한 관리: IDYA의 경영진은 경험이 있음으로 간주됩니다(평균 재임 2.4 년).

이사회 구성원

이름직위재임 기간보수지분
Yujiro Hata
Founder10.9yrsUS$9.51m0.79%
$ 20.4m
Wendy Yarno
Independent Director6.4yrsUS$344.16k데이터 없음
Jeffrey Stein
Independent Director10.6yrsUS$351.66k0.069%
$ 1.8m
Frank McCormick
Chair of Scientific Advisory Board7.3yrs데이터 없음데이터 없음
Scott William Morrison
Independent Director7.8yrsUS$351.66k데이터 없음
Catherine Mackey
Independent Director4.1yrsUS$334.16k데이터 없음
Trey Ideker
Member of Scientific Advisory Board10yrs데이터 없음데이터 없음
William Sellers
Member of Scientific Advisory Board7.3yrs데이터 없음데이터 없음
Elizabeth Swisher
Member of Scientific Advisory Board10yrs데이터 없음데이터 없음
Terry Rosen
Independent Chairman of the Board10.3yrsUS$379.16k0.0093%
$ 241.4k
Malcolm Hampton
Independent Director5.9yrsUS$331.66k데이터 없음
Karlene Cimprich
Member of Scientific Advisory Board3.4yrs데이터 없음데이터 없음
7.5yrs
평균 재임 기간
67yo
평균 나이

경험이 풍부한 이사회: IDYA의 이사회는 경험이 있음으로 간주됩니다(평균 재임 7.5 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/22 09:16
종가2026/05/22 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

IDEAYA Biosciences, Inc.는 32명의 분석가가 다루고 있습니다. 이 중 17명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Madhu KumarBaird
Zhiqiang ShuBerenberg
Suranjit MukherjeeBTIG